无障碍说明

BRIEF-Chemocentryx says granted EU orphan drug designation for avacopan in treating patients with C3G

May 23 (Reuters) - Chemocentryx Inc (CCXI.O)

* Says granted EU orphan drug designation for avacopan in treatment of debilitating kidney disease C3 glomerulopathy

* Says plans to initiate a multi-center clinical endpoint study of avacopan for treatment of c3g in mid-2017

Source text for Eikon: Further company coverage: (CCXI.O)

正文已结束,您可以按alt+4进行评论
收藏本文

相关搜索

热门搜索

为你推荐